A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Status:
Completed

Trial end date:
2014-09-15

Target enrollment:

Participant gender:

This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.

Phase 2

Astellas Pharma Inc

Darbepoetin alfa